Latest
The latest peptide research news, clinical trial results, and industry updates from trusted sources.
481 articles
Matexcel Enhances Bioactive Peptides Offering for Research Applications - 24 Source: 24-7 Press Release Newswire Read the full article at the original source for complete details.
Hangzhou Thinheal Pharma-Tech Co., Ltd. to Showcase Peptide Innovation at FCE Pharma 2026 in São Paulo FinancialContent
Opinion | Beware the risks of ‘wellness’ peptides Source: The Washington Post Read the full article at the original source for complete details.
EDTA enhances antimicrobial activity of PR-39 and Protegrin-1 antimicrobial peptides against carbapenem-resistant Pseudomonas aeruginosa in serum. Vacek L(1), Pavelka A(2)(3), Lipový B(4)(5), Brtníková J(5), Straková P(2), Jeklová E(2), Šefranko M(1), Kleknerová DP(1), Volný F(1), Janda L(2), Vojtová L(5), Růžička F(6). Author information: (1)Department of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Pekařská 53, Brno, 602 00, Czech Republic. (2)Infectious Diseases and Preventive Medicine, Veterinary Research Institute, Hudcova 296/70, Brno, 621 00, Czech Republic. (3)National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic. (4)Department of Burns Medicine, Third Faculty of Medicine, Charles University, University Hospital Královské Vinohrady, Šrobárova 50, Prague, 100 34, Czech Republic. (5)Advanced Biomaterials Group, Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, Brno, 612 00, Czech Republic. (6)Department of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Pekařská 53, Brno, 602 00, Czech Republic. filip.ruzicka@fnusa.cz. Carbapenem-resistant Pseudomonas aeruginosa represents a frequent and clinically challenging pathogen responsible for both acute and chronic infections. Antimicrobial peptides are emerging as a promising class of novel therapeutic agents due to their broad-spectrum activity, rapid bactericidal activity, and low potential to induce antimicrobial resistance. The antimicrobial efficacy of these peptides can be further enhanced by EDTA. However, their activity is often reduced in the presence of serum, which contains multiple inhibitory components. In this study, EDTA fully restored the antimicrobial activity of PR-39 and Protegrin-1 in serum. Moreover, incorporation of chitosan increased the antimicrobial efficacy of the PR-39/Protegrin-1/EDTA formulation. These findings demonstrate that PR-39, Protegrin-1, EDTA, and chitosan can act synergistically, supporting the feasibility of integrating these components into a unified therapeutic platform. © 2026. The Author(s). Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests.
Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database. Anatriello A(#)(1)(2), Liguori V(#)(1)(2), Pentella C(1)(2), Zinzi A(3)(4)(5), Longo M(6)(7), Caruso P(8), Maiorino MI(7)(8), Esposito K(7)(8), Capuano A(1)(2). Author information: (1)Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy. (2)Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. (3)Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy. a.zinzi@unilink.it. (4)Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. a.zinzi@unilink.it. (5)Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy. a.zinzi@unilink.it. (6)Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy. (7)Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. (8)Division of Endocrinology and Metabolic Diseases, University of Campania "Luigi Vanvitelli", Naples, Italy. (#)Contributed equally INTRODUCTION: The therapeutic landscape for the treatment of type 2 diabetes mellitus (T2DM) has greatly evolved with the introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); however, concerns regarding their potential association with thyroid cancer have emerged. The aim of this study is to analyze individual case safety reports (ICSRs) involving GLP-1 RAs, focusing on thyroid cancer-related adverse events (AEs) using the European pharmacovigilance database. METHODS: ICSRs reporting GLP-1 RAs (semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide) or the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide as suspected drugs were retrieved from the EudraVigilance (EV) database from 1st January 2022 to 26th September 2024. A disproportionality analysis was performed to compare the probability of reporting thyroid cancer-related AEs among these drugs using the reporting odds ratio (ROR) and its 95% confidence interval (95% CI). Considering the different therapeutic indications, a sensitivity analysis was also conducted. RESULTS: A total of 34,956 ICSRs were included in the analysis. The majority of AEs were experienced by adult and elderly female patients. The most reported system organ classes (SOCs) were: "gastrointestinal disorders", "general disorders and administration site conditions", and "injury, poisoning and procedural complications". Disproportionality analysis revealed that semaglutide had a lower probability of reporting thyroid cancer-related AEs than tirzepatide (ROR = 0.54, 95% CI 0.37-0.81, p < 0.05), whereas sensitivity analysis revealed no significant signals across stratified therapeutic groups. CONCLUSION: These findings should be interpreted with caution, given the inherent limitations of pharmacovigilance databases. Further studies are recommended to better assess the potential causal relationship between GLP-1 RAs and thyroid cancer. © 2026. The Author(s). Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests.
Get the latest research news and industry updates sent to your inbox weekly. No spam, unsubscribe anytime.
For research purposes only. Unsubscribe anytime.